quinuclidine selective cholinergic agonist cognitive dysfunctions animal model Alzheimer disease quinuclidine rigid analog acetylcholine number neurochemical pharmacological behavioral tests cholinergic functions atropine-sensitive contractions isolated guinea pig ilea trachea preparations values microM potent acetylcholine studies radioligands cis-dioxolane quinuclidinyl benzilate rat cerebral cortex quinuclidinyl benzilate cerebellar homogenates potent selective muscarinic probe selective receptors oxotremorine carbachol trans-isomer apparent affinity receptors prototype agonist cis- rigid analogs acetylcholine Treatment rat cortical homogenates Cu++ ions affinity muscarinic antagonists scopolamine pirenzepine proportion high affinity sites agonists carbachol apparent affinity Cu++ treatment compound rat cerebral cortex muscarinic receptors agonist high affinity choline transport choline acetyltransferase acetylcholinesterase activities rat brain preparations rats cholinotoxin ethylcholine aziridinium ion mg/kg p.o i.p mg/kg i.p mg/kg i.p physostigmine mg/kg i.p cognitive impairments step-through passive avoidance task mg/kg i.p mg/kg i.p effective reference memory impairments Morris water maze test Repetitive administrations mg/kg/day i.p working memory deficits Morris water maze test open field behavior data show selective agonist cognitive impairments adverse central peripheral side effects effective doses potential use treatment Alzheimer disease 